Atlas Trials

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

Clinical trial NCT03141086 · TERMINATED

Trial details

NCT number
NCT03141086
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Circadian Rhythm Disorders
Start date
2017-07-26
Primary completion
2018-08-30
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.